Neuro-Oncology · 2018 · 86 citations · 38 references
MedicineCancer BiologyOncologyCancer PharmacologyMolecular OncologyTumor ProgressionAngiogenesisAngiogenesis In CancerCancer Cell SignalingGlioblastomaGrowth Factor SignalingTargeted Cancer TherapyGlioblastoma Therapeutic ResistancePrimary Cell CultureVascular Endothelial Growth FactorVascular Endothelial Growth Factor Receptor SignalingVascular Endothelial Growth Factor ReceptorsVascular Endothelial Growth Factor SignalingVascular Endothelial Growth Factor-c SignalingVegf-c Signaling
Background: Glioblastoma ranks among the most lethal cancers, with current therapies offering only palliation. Paracrine vascular endothelial growth factor (VEGF) signaling has been targeted using anti-angiogenic agents, whereas autocrine VEGF/VEGF receptor 2 (VEGFR2) signaling is poorly understood. Bevacizumab resistance of VEGFR2-expressing glioblastoma cells prompted interrogation of autocrine VEGF-C/VEGFR2 signaling in glioblastoma. Methods: Autocrine VEGF-C/VEGFR2 signaling was functionally investigated using RNA interference and exogenous ligands in patient-derived xenograft lines and primary glioblastoma cell cultures in vitro and in vivo. VEGF-C expression and interaction with VEGFR2 in a matched pre- and post-bevacizumab treatment cohort were analyzed by immunohistochemistry and proximity ligation assay. Results: VEGF-C was expressed by patient-derived xenograft glioblastoma lines, primary cells, and matched surgical specimens before and after bevacizumab treatment. VEGF-C activated autocrine VEGFR2 signaling to promote cell survival, whereas targeting VEGF-C expression reprogrammed cellular transcription to attenuate survival and cell cycle progression. Supporting potential translational significance, targeting VEGF-C impaired tumor growth in vivo, with superiority to bevacizumab treatment. Conclusions: Our results demonstrate VEGF-C serves as both a paracrine and an autocrine pro-survival cytokine in glioblastoma, promoting tumor cell survival and tumorigenesis. VEGF-C permits sustained VEGFR2 activation and tumor growth, where its inhibition appears superior to bevacizumab therapy in improving tumor control.
38
Roger Stupp, Monika E. Hegi, Warren Mason et al. · The Lancet Oncology · 2009 · 7.8K citations
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert, James J. Dignam, Terri S. Armstrong et al. · New England Journal of Medicine · 2014 · 2.8K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Lomustine and Bevacizumab in Progressive Glioblastoma
Wolfgang Wick, Thierry Gorlia, Martin Bendszus et al. · New England Journal of Medicine · 2017 · 978 citations · Full text
Medicine, Oncology, Pharmacotherapy +17